单位：[1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China内科学系血液内科华中科技大学同济医学院附属同济医院[2]Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China华中科技大学同济医学院附属协和医院[3]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, Hubei 430030, China.内科学系血液内科华中科技大学同济医学院附属同济医院[4]Key Laboratory of Organ Transplantation, Ministry of Education[5]National Health Commission (NHC)[6]Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei 430030, China.[7]Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, and Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi 030032, China[8]Sino-German Joint Oncological Research Laboratory, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, Shanxi 030032, China
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has been found that both innate and adaptive immune signaling are activated in the hematopoietic niche of MDS with aberrant cytokine secretion in the bone marrow microenvironment. It is also clear that immune dysregulation plays an important role in the occurrence and progression of MDS, especially the destruction of the bone marrow microenvironment, including hematopoiesis and stromal components. The purpose of this review is to explore the role of immune cells, the immune microenvironment, and cytokines in the pathogenesis of MDS. Insights into the mechanisms of these variants may facilitate the development of novel effective treatments to prevent disease progression.
基金：
National
High Technology Research and Development
Program of China (grant no. 2021YFA1101504
to Dr Yicheng Zhang), and the National Natural
Science Foundation of China (grant no.
81873427 to Dr Jia Wei, grant no. 81873446 to
Dr Yicheng Zhang, grant no. 81900133 to Dr.
Ling Ma).
第一作者单位：[1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
通讯作者：
通讯机构：[3]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, Hubei 430030, China.[4]Key Laboratory of Organ Transplantation, Ministry of Education[5]National Health Commission (NHC)[6]Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei 430030, China.[7]Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, and Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi 030032, China[8]Sino-German Joint Oncological Research Laboratory, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, Shanxi 030032, China
推荐引用方式(GB/T 7714)：
Zhang Xiaoying,Yang Xingcheng,Ma Ling,et al.Immune dysregulation and potential targeted therapy in myelodysplastic syndrome[J].Therapeutic advances in hematology.2023,14:doi:10.1177/20406207231183330.
APA：
Zhang, Xiaoying,Yang, Xingcheng,Ma, Ling,Zhang, Yicheng&Wei, Jia.(2023).Immune dysregulation and potential targeted therapy in myelodysplastic syndrome.Therapeutic advances in hematology,14,
MLA：
Zhang, Xiaoying,et al."Immune dysregulation and potential targeted therapy in myelodysplastic syndrome".Therapeutic advances in hematology 14.(2023)
：